Despite the excellent efficacy of anti-VEGFs in reducing macular edema and the subsequent rapid improvement of visual acuity, in many patients, the efficacy tends to decline when injection frequency is reduced [51], while in others, persistent macular edema is obvious, despite intensive VEGF treatment [52]. This evidence concerns the gene VEGFA and macular retinal edema.